KRAS and pancreatic neoplasm: Previous studies have demonstrated that oncogenic GTPase KRAS mutation is involved in the initiation of pancreatic intraepithelial neoplasia and activates the progression of pancreatic cancer, especially pancreatic ductal adenocarcinoma [10] [11] [12] [18].